company dropping glp-1 coverage 2025 GLP-1s and the Future of Workforce GLP-1 Market Trends and Global

(Exenatide is FDA approved as monotherapy for the management of T2DM.) Explicitly stated in the guideline for patients requiring dual or triple therapy, the AACE/ACE preferentially recommends the addition of a GLP-1 receptor agonist or a DPP-4 inhibitor (sitagliptin, saxagliptin), citing their efficacy and safety profiles as preferred agents over TZDs or sulfonylureas (SUs)

seen on the lip, the tongue, inside the mouth Based on the variants, they may be classified as: Volar Melanotic Macule, which is seen in the palms and soles Ungual Melanotic Macule, involving the nail apparatus Reticulated Melanotic Macule, developing on the skin due to sun-exposure PUVA-Lentigines, which occurs as a side effect of PUVA therapy given for various skin conditions The presence of numerous Melanotic Macules on the body may be associated with a variety of syndromes including Carney complex, Peutz-Jeghers syndrome, and LEOPARD syndrome

To mitigate these risks, the concurrent use of gastroprotective agents, such as proton pump inhibitors (PPIs), is advised in at-risk populations (Pelletier et al., 2016

Notably, oral semaglutide (Wegovy) became the first oral GLP-1 approved for weight loss and weight loss plus secondary CV risk reduction